To determine whether BIRC5 can serve as an effective biomarker for lung cancer prognosis, we used receiver operating characteristic (ROC) curves to evaluate its predictive performance for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in lung cancer patients at 1, 3, and 5 years. The gene discussed is BIRC5; the disease is lung carcinoma.